• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

我们2014年应对侵袭性真菌突破性感染的方法。

Our 2014 approach to breakthrough invasive fungal infections.

作者信息

Maschmeyer Georg, Patterson Thomas F

机构信息

Department of Hematology, Oncology and Palliative Care, Klinikum Ernst von Bergmann, Academic Teaching Hospital of the Charité University Medicine of Berlin, Potsdam, Germany.

出版信息

Mycoses. 2014 Nov;57(11):645-51. doi: 10.1111/myc.12213. Epub 2014 Jun 25.

DOI:10.1111/myc.12213
PMID:24963554
Abstract

Evidence-based clinical pathways to direct antifungal treatment options in patients with breakthrough fungal infections during current systemic antifungal therapy are not available. Nonetheless, for defined settings of such breakthrough infections approaches to management can be recommended based on clinical, epidemiological, pharmacological and in vitro susceptibility data.

摘要

目前尚无基于循证的临床路径来指导接受全身性抗真菌治疗期间发生突破性真菌感染的患者选择抗真菌治疗方案。尽管如此，对于此类突破性感染的特定情况，可根据临床、流行病学、药理学及体外药敏数据推荐管理方法。

相似文献

1
Our 2014 approach to breakthrough invasive fungal infections.我们2014年应对侵袭性真菌突破性感染的方法。
Mycoses. 2014 Nov;57(11):645-51. doi: 10.1111/myc.12213. Epub 2014 Jun 25.
2
New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.新型三唑类和棘白菌素类药物：作用模式、体外活性和耐药机制。
Expert Rev Anti Infect Ther. 2009 Oct;7(8):981-98. doi: 10.1586/eri.09.67.
3
Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review.棘白菌素类药物治疗后突破性侵袭性真菌感染的特征：基于证据的综述。
Int J Antimicrob Agents. 2010 Mar;35(3):211-8. doi: 10.1016/j.ijantimicag.2009.09.020. Epub 2009 Dec 29.
4
Recent advances and challenges in the treatment of invasive fungal infections.侵袭性真菌感染治疗的最新进展与挑战
Int J Antimicrob Agents. 2007 Dec;30(6):487-95. doi: 10.1016/j.ijantimicag.2007.07.019. Epub 2007 Oct 24.
5
Role of antifungal susceptibility testing in patient management.抗真菌药敏试验在患者管理中的作用。
Curr Opin Infect Dis. 2006 Dec;19(6):538-43. doi: 10.1097/QCO.0b013e328010682c.
6
Aspergillus to Zygomycetes: causes, risk factors, prevention, and treatment of invasive fungal infections.从曲霉到接合菌：侵袭性真菌感染的病因、危险因素、预防及治疗
Infection. 2008 Aug;36(4):296-313. doi: 10.1007/s15010-008-7357-z. Epub 2008 Jul 19.
7
Changing strategies for the management of invasive fungal infections.侵袭性真菌感染管理策略的转变
Pharmacotherapy. 2004 Feb;24(2 Pt 2):4S-28S; quiz 29S-32S.
8
Posaconazole: clinical pharmacology and potential for management of fungal infections.泊沙康唑：临床药理学及真菌感染管理潜力
Expert Rev Anti Infect Ther. 2005 Aug;3(4):467-87. doi: 10.1586/14787210.3.4.467.
9
New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage.治疗真菌感染的新型药物：临床疗效与覆盖范围的差距
Clin Infect Dis. 2006 Oct 15;43(8):1060-8. doi: 10.1086/507891. Epub 2006 Sep 8.
10
Emerging moulds: epidemiological trends and antifungal resistance.新兴霉菌：流行病学趋势和抗真菌耐药性。
Mycoses. 2011 Nov;54(6):e666-78. doi: 10.1111/j.1439-0507.2011.02032.x. Epub 2011 Jun 14.

引用本文的文献

1
Breakthrough Invasive Fungal Infections in Patients With High-Risk Hematological Disorders Receiving Voriconazole and Posaconazole Prophylaxis: A Systematic Review.高危血液系统疾病患者接受伏立康唑和泊沙康唑预防治疗后突破性侵袭性真菌感染：系统评价。
Clin Infect Dis. 2024 Jul 19;79(1):151-160. doi: 10.1093/cid/ciae203.
2
Amphotericin B in the Era of New Antifungals: Where Will It Stand?新型抗真菌药物时代的两性霉素B：它将何去何从？
J Fungi (Basel). 2024 Apr 10;10(4):278. doi: 10.3390/jof10040278.
3
High-Risk Neutropenic Fever and Invasive Fungal Diseases in Patients with Hematological Malignancies.
血液系统恶性肿瘤患者的高危中性粒细胞减少性发热和侵袭性真菌病
Microorganisms. 2024 Jan 6;12(1):117. doi: 10.3390/microorganisms12010117.
4
Real-World, Multicenter Case Series of Patients Treated with Isavuconazole for Invasive Fungal Disease in China.中国使用艾沙康唑治疗侵袭性真菌病的真实世界多中心病例系列
Microorganisms. 2023 Sep 4;11(9):2229. doi: 10.3390/microorganisms11092229.
5
Case reports of invasive mucormycosis associated neutropenic enterocolitis in leukemic children: diagnostic and treatment challenges and review of literature.白血病儿童中性粒细胞减少性肠内侵袭性毛霉菌病病例报告：诊断和治疗挑战及文献复习。
BMC Infect Dis. 2021 Dec 20;21(1):1268. doi: 10.1186/s12879-021-06957-0.
6
Lethal thrombosis of the iliac artery caused by Aspergillus fumigatus after liver transplantation: case report and review of the literature.肝移植后烟曲霉引起的髂动脉致死性血栓形成：病例报告及文献复习
BMC Surg. 2019 Dec 27;19(1):200. doi: 10.1186/s12893-019-0668-4.
7
Defining breakthrough invasive fungal infection-Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology.定义突破性侵袭性真菌感染——医学真菌学研究组教育和研究联盟及欧洲医学真菌学会联合会立场文件。
Mycoses. 2019 Sep;62(9):716-729. doi: 10.1111/myc.12960. Epub 2019 Jul 19.
8
Isavuconazole in the Treatment of Coccidioidal Meningitis.伊曲康唑治疗球孢子菌性脑膜炎。
Antimicrob Agents Chemother. 2019 Feb 26;63(3). doi: 10.1128/AAC.02232-18. Print 2019 Mar.
9
Risk factors and clinical outcomes of breakthrough yeast bloodstream infections in patients with hematological malignancies in the era of newer antifungal agents.新型抗真菌药物时代血液系统恶性肿瘤患者突破性酵母菌血流感染的危险因素及临床结局
Med Mycol. 2018 Feb 1;56(2):197-206. doi: 10.1093/mmy/myx038.
10
Prescribing Pattern of Antifungal Medications at a Tertiary Care Hospital in Oman.阿曼一家三级医疗医院抗真菌药物的处方模式。
J Clin Diagn Res. 2016 Dec;10(12):FC27-FC30. doi: 10.7860/JCDR/2016/23591.9005. Epub 2016 Dec 1.